Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Orchestra BioMed secures $15M from Ligand to fund pivotal trials of cardiovascular therapies.
MDT
$80.48
+$0.01 +0.01%

Orchestra BioMed secures $15M from Ligand to fund pivotal trials of cardiovascular therapies.

Company Fundamentals
06 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Orchestra BioMed received a $15 million payment from Ligand Pharmaceuticals as part of a previously agreed royalty-based financing deal, bringing Ligand's total investment to $40 million. This funding supports ongoing pivotal clinical trials for Orchestra BioMed's cardiovascular therapies, AVIM Therapy and Virtue SAB, which target hypertension and artery disease. The capital injection, combined with a separate $20 million investment from Medtronic, totals $35 million received on May 1, 2026, enabling continued development and potential market advancement of these therapies. The partnerships with Ligand and Medtronic highlight confidence in Orchestra BioMed’s progress and future milestones in cardiovascular treatment innovation.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App